IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#1835
Positioning
Market Dominance
Services
Computer Software
$837M
Robert A. Frist
HealthStream, Inc. provides workforce and provider solutions for healthcare organizations in the United States. The company offers software-as-a-service (SaaS) based services and subscription-based solutions. It also provides VerityStream that delivers enterprise-class solutions to transform the healthcare provider experience for ambulatory surgery centers, urgent care facilities, clinics, medical groups, and other healthcare organizations.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Dates updated upon official exchange announcement.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
X-AXIS: EV/EBITDA (LOWER = CHEAPER) | Y-AXIS: ROE (HIGHER = ELITE) | RED CIRCLE = HSTM ANALYSIS TARGET
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$YALA Yalla Group Ltd | 75 | 89 | 99 | 80 | - | - | 21.3% | 18.6% | 64.5% | 35.7% | 39.5% | 6.5% | 0.0% | 0.0x | $644M | VS | |
$GRVY GRAVITY Co., Ltd. | 75 | 82 | 96 | 71 | - | - | 15.4% | 12.6% | 38.7% | 17.1% | 17.0% | -39.7% | 0.0% | 0.0x | $439M | VS | |
$ISSC INNOVATIVE SOLUTIONS & SUPPORT INC | 73 | 81 | 88 | 94 | 25.0x | 14.1x | 28.1% | 16.8% | 48.1% | 23.8% | 18.5% | 78.6% | 0.0% | 37.0x | $220M | VS | |
$AER AerCap Holdings N.V. | 72 | 60 | 87 | 84 | - | - | 12.4% | 2.9% | 100.0% | 28.2% | 26.2% | 5.5% | 0.8% | 264.0x | $19.4B | VS | |
$HCSG HEALTHCARE SERVICES GROUP INC | 72 | 74 | 88 | 88 | 7.1x | 6.1x | 28.9% | 20.8% | 20.8% | 9.9% | 9.3% | 8.5% | 0.0% | 1.0x | $1.2B | VS | |
$LQDT LIQUIDITY SERVICES INC | 72 | 90 | 88 | 68 | 24.9x | 14.3x | 14.6% | 7.8% | 43.8% | 7.4% | 5.9% | 31.2% | 0.0% | 0.0x | $857M | VS | |
$TRTNpA Triton International Ltd | 71 | 70 | 89 | 70 | - | 1.7x | 18.0% | 4.6% | 97.3% | 52.2% | 32.7% | -3.4% | 0.0% | 271.0x | $8.0B | VS | |
$EDU New Oriental Education & Technology Group Inc. | 71 | 83 | 52 | 77 | - | - | 9.4% | 4.9% | 55.5% | 8.7% | 7.7% | 13.6% | 1.3% | 7.0x | $78.0B | VS | |
$NTES NetEase, Inc. | 71 | 88 | 93 | 68 | - | - | 22.1% | 15.6% | 62.5% | 28.1% | 28.7% | -1.0% | 2.8% | 9.0x | $56.6B | VS | |
$UTI UNIVERSAL TECHNICAL INSTITUTE INC | 70 | 86 | 86 | 72 | 43.2x | 16.0x | 21.4% | 8.0% | 100.0% | 10.0% | 7.5% | 14.1% | 0.0% | 27.0x | $1.8B | VS | |
$HSTM HEALTHSTREAM INC | 51 | 56 | 67 | 37 | 28.0x | 24.8x | 6.2% | 4.3% | 65.0% | 8.2% | 7.2% | 6.9% | 0.4% | 43.0x | $837M | ||
| SECTOR BENCH | - | - | - | - | - | 23.7x | 11.7x | 5.3% | 1.9% | 59.6% | 3.5% | 2.3% | 7.8% | 0.0% | 0.3x | - | REF |
HEALTHSTREAM INC (HSTM) receives a "Hold" rating with a composite score of 51.2/100. It ranks #1835 out of 7,333 stocks in our coverage universe and carries a 3-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
YOY expansion rate
Core pricing power
Operating efficiency
Bottom-line conversion
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
Robert A. Frist
Chief Executive Officer
Labor Force
1,140
56
30
86
Audit Verdict: Average governance indicators based on financial metrics.
No recent insider transactions available for HSTM
Lagging peers — losers tend to keep underperforming
Trading at a discount to fundamentals — favorable entry valuation
Average quality profile
Low volatility — smoother ride and historically better risk-adjusted returns
Aggressive spending — empire-building risk, dilutive growth
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Services sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
Projection based on user-defined inputs. Re-calculated daily against current market data.
Reverse DCF Framework — Mauboussin Methodology
Institutional-grade Reverse DCF analysis. This model identifies the growth hurdles embedded in current market prices. When implied growth is significantly lower than historical or projected rates, a margin of safety may exist. Re-audited daily.
No analyst ratings for HSTM.
View All RatingsConservative accounting — High cash conversion efficiency
Material decline in asset turnover efficiency detected
| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 56 | 69 | -13DRAG |
| MOMENTUM | 37 | 33 | +4NEUTRAL |
| VALUATION | 67 | 76 | -9DRAG |
| INVESTMENT | 30 | 33 | -3NEUTRAL |
| STABILITY | 86 | 94 | -8DRAG |
| SHORT INT | 34 | 23 | +11ALPHA |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROE proxy 6.2% (sector 5.3%)
GM 65% vs sector 60%, OM 8% vs sector 4%
Capital turnover N/A, R&D intensity 16.1%
Rev growth 7%, 10yr history
Interest coverage N/A, Net debt/EBITDA -7.1x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Our model assigns HEALTHSTREAM INC a Hold rating, with a composite score of 51.2/100 and 3 out of 5 stars. Ranked #1835 of 7,333 stocks, HSTM presents a mixed quantitative picture — neither compelling enough to initiate new positions nor weak enough to warrant selling. Investors already holding may consider maintaining their position while monitoring for changes in the factor profile.
With a quality score of 56/100, HSTM shows adequate but unremarkable business quality. The company reports a return on equity of 6.2% (sector avg: 5.3%), gross margins of 65.0% (sector avg: 59.6%), net margins of 7.2% (sector avg: 2.3%). This suggests the company generates acceptable returns but may lack the competitive positioning or operational efficiency to stand out from peers.
HSTM's value score of 67/100 indicates the stock is fairly valued based on its current fundamentals. Key valuation metrics include a P/E ratio of 28.04x, an EV/EBITDA of 24.82x, a P/B ratio of 1.73x. At this level, neither a clear bargain nor overpriced, the stock's attractiveness depends more on forward growth expectations and qualitative factors.
HEALTHSTREAM INC's investment score of 30/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of 6.9% vs. a sector average of 7.8% and a return on assets of 4.3% (sector: 1.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
HSTM is currently showing below-average momentum at 37/100, which may indicate weakening institutional interest or negative sentiment shifts. Revenue growth stands at 6.9% year-over-year, while a beta of 0.50 reflects its sensitivity to broader market moves. Investors should note that declining momentum can precede further price weakness, though contrarian opportunities sometimes emerge at these levels.
HEALTHSTREAM INC earns an excellent stability score of 86/100, reflecting low price volatility and a conservatively managed balance sheet. Key stability metrics include a beta of 0.50 and a debt-to-equity ratio of 43.00x (sector avg: 0.3x). Stocks with this level of stability tend to act as portfolio anchors, providing downside protection during market corrections while still participating in broad market advances.
HEALTHSTREAM INC's short interest score of 34/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include elevated leverage (D/E: 43.00x), small-cap liquidity risk. At $837M (small-cap), HSTM carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
HSTM offers a modest dividend yield of 0.4%. While the income contribution is relatively small, even a small dividend signals management's commitment to shareholder returns and can serve as a signal of financial discipline.
HEALTHSTREAM INC is a small-cap company in the Services sector, ranked #0 of 50 in its sector (100th percentile) and #1835 of 7,333 overall (75th percentile). Key comparisons include ROE of 6.2% exceeding the 5.3% sector median and operating margins of 8.2% above the 3.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Services peers.
While HSTM currently exhibits a HOLD profile, superior opportunities exist within the SERVICES sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Services Alpha →Quant Factor Profile
Key factor gap
Stability (86) vs Investment (30) — closing this gap could shift the rating.
EV/EBITDA 112% ABOVE SECTOR MEDIAN
ROE 16% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 9% ABOVE SECTOR MEDIAN (FAVORABLE)
AUDIT DATA AS OF SEP 30, 2025 (Q2 FY2025)
We rate HEALTHSTREAM INC (HSTM) as a Hold with a composite score of 51.2/100 at a current price of $22.11. The stock presents a mixed quantitative picture — neither compelling enough to warrant new accumulation nor weak enough to justify selling for existing holders. Our factors are split, and the overall profile suggests patience is warranted.
The rating is primarily driven by strength in stability (86th percentile) and value (67th percentile), which together account for the majority of the composite score. Offsetting weakness in investment (30th percentile) and momentum (37th percentile) tempers our overall conviction. We assign a Narrow Moat rating (46/100), Low uncertainty, and Poor capital allocation.
Key items to watch: momentum to confirm whether the current price trend has legs. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
HEALTHSTREAM INC holds a top-quartile position (#0 of 50) within the Services sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 51.2/100 places it at rank #1835 in our full 7,333-stock universe. At $837M in market capitalization, HEALTHSTREAM INC is a small-cap player in the Services space, which limits certain scale advantages but may allow for more agile strategic execution.
Revenue is growing at 7%, though momentum at the 37th percentile suggests the market has not yet fully recognized this trajectory. This potential disconnect between fundamental improvement and market recognition could represent an opportunity for patient investors if the growth trend persists.
The margin cascade tells an important story: gross margins of 65% (+5.4pp vs sector) narrow to operating margins of 8% (+4.7pp vs sector) and net margins of 7.2%, yielding a gross-to-net conversion rate of 11%. The significant margin erosion from gross to net suggests elevated operating expenses, high interest costs, or other structural drags that warrant monitoring.
At a current price of $22.11, HEALTHSTREAM INC is trading near fair value based on current fundamentals. Our value factor score of 67/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. Valuation metrics are mixed, with no strong signal of mispricing in either direction.
The stock currently trades at a P/E of 28.0x (roughly in line with the sector median of 23.7x), EV/EBITDA of 24.8x (at a premium), P/B of 1.7x, P/S of 2.0x. The above-sector P/E multiple suggests the market is pricing in superior growth or quality, which our analysis finds only partially justified by current fundamentals.
Gross margins of 65% signal strong pricing power and brand/IP advantages — businesses with margins above 40% have historically demonstrated more resilient earnings through economic cycles.
A value factor score of 67/100 suggests the market is underpricing these fundamentals, creating a potential margin of safety for new investors.
Even high-quality stocks face risks from valuation compression, competitive disruption, or macro shocks that are difficult to quantify in advance.
We assign a Low uncertainty rating to HEALTHSTREAM INC. The company exhibits strong financial stability with a beta of 0.50, conservative leverage (43% D/E), and a stability factor in the 86th percentile. The predictable nature of the business model and solid financial position reduce the range of potential outcomes, giving us confidence in our fair value estimate.
Specific risk factors that inform our assessment include: low beta of 0.50 — while defensive, this may indicate limited upside participation in bull markets. Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 86th percentile and quality factor at the 56th percentile provide a quantitative summary of the overall risk landscape.
Key risk mitigants include: healthy gross margins of 65% provide a buffer against cost pressures; above-average stability (86th percentile) suggests predictable business dynamics. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile is favorable for long-term investors.
We rate HEALTHSTREAM INC's capital allocation as Poor. Key concerns include suboptimal returns on capital. Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — HEALTHSTREAM INC significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, HEALTHSTREAM INC receives a Hold rating with a composite score of 51.2/100 (rank #1835 of 7,333). Our quantitative framework assigns a Narrow Moat (46/100, trend: stable), Low uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 55/100.
Our analysis supports a neutral stance on HEALTHSTREAM INC. While the quantitative profile is not weak enough to warrant selling, it lacks the multi-factor strength required for a buy recommendation. Existing holders should maintain positions and monitor for catalysts — either fundamental improvement or valuation compression — that would shift the risk-reward balance.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We assign HEALTHSTREAM INC a Narrow Moat rating with a composite moat score of 46/100. The company possesses identifiable competitive advantages, though they are less entrenched than those of wide-moat peers. Our analysis indicates that HEALTHSTREAM INC can sustain above-average returns on invested capital for at least 10 years, with the strongest contributor being margin superiority at 14.4/20.
The strongest moat sources are margin superiority (14.4/20) and growth durability (9.9/20). GM 65% vs sector 60%, OM 8% vs sector 4%. Rev growth 7%, 10yr history. These pillars form the core of HEALTHSTREAM INC's competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include reinvestment efficiency (5.7/20) and economic value creation (5.8/20). Capital turnover N/A, R&D intensity 16.1%. Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect HEALTHSTREAM INC's moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers include gross margins of 65% providing a solid profitability foundation, moderate revenue growth of 7%. The margin cascade from 65% gross to 8% operating to 7.2% net reveals the company's cost structure and reinvestment intensity. Our analysis indicates that profit quality is adequate though not exceptional, with the quality factor at the 56th percentile.
The margin profile shows gross margins of 65%, operating margins of 8%, net margins of 7.2%. Return metrics include ROE of 6.2% and ROA of 4.3%. Relative to the Services sector, gross margins are 5.4 percentage points above the sector median of 60%, and ROE of 6.2% compares to a sector median of 5.3%.
The balance sheet reflects moderate leverage with D/E of 43%, a dividend yield of 0.43%, revenue growth of 7%. The sector median D/E is 0%, putting HEALTHSTREAM INC at higher leverage than the typical peer. Overall balance sheet health is adequate for the current business environment.
HealthStream (HSTM) raises its quarterly dividend 12.9% to $0.035/share (0.66% forward yield).
HealthStream (HSTM) Q4 earnings: EPS and revenue beats, EBITDA up 16%, acquisitions, and $10M buyback.
NASHVILLE, Tenn., February 23, 2026--HealthStream, Inc. (the "Company") (Nasdaq: HSTM), a leading healthcare technology platform company for clinical workforce solutions, announced today results for the fourth quarter and full-year ended December 31, 2025.

Gainers InMed Pharmaceuticals Inc. (NASDAQ: INM) shares climbed 169% to $1.56 after the company announced it selected a lead Alzheimer's drug candidate following proof-of-concept study data. LianBio (NASDAQ: LIAN) shares climbed 94.3% to $2.7003 after the company entered into agreement with Bristol Myers Squibb for Mavacamten in China and other Asian markets. Ascent Solar Technologies, Inc. (NASDAQ: ASTI) climbed 78.1% to $1.7499 after the company received encouragement from the U.S. Department of Energy to submit a full application for federal funding of the Agrivoltaic Product Development Project. Falcon's Beyond Global, Inc. (NASDAQ: FBYD) gained 36.8% to $17.53. ImmunityBio, Inc. (NASDAQ: IBRX) jumped 31.4% to $1.88. AERWINS Technologies Inc. (NASDAQ: AWIN) shares climbed 29.9% to $0.1481 after falling 10% on Monday. Aspen Aerogels, Inc. (NASDAQ: ASPN) rose 27.8% to $8.52. SAI.TECH Global Corporation (NYSE: SAI) climbed 26.6% to $1.14. Mullen Automotive, Inc. (NASDAQ: MULN) gained 26.4% to $0.2829. Digihost Technology Inc. (NASDAQ: DGHI) rose 26.2% to $1.59. Travelzoo (NASDAQ: TZOO) surged 24.8% to $6.56 following strong quarterly results. Yoshiharu Global Co. (NASDAQ: YOSH) gained 23.6% to $0.5440. Agilysys, Inc. (NASDAQ: AGYS) gained 21.5% to $77.62 after it reported second-quarter results. Mawson Infrastructure Group, Inc. (NASDAQ: MIGI) rose 20.2% to $0.8420. Iris Energy Limited (NASDAQ: IREN) gained 18.7% to $3.7977. Iris Energy partnered with WEKA to optimize generative AI workloads. Stitch Fix, Inc. (NASDAQ: SFIX) climbed 17.7% to $3.7550. Nikola Corporation (NASDAQ: NKLA) jumped 17.3% to $1.1197. Nikola, on Oct 20, said an arbitration panel in New York, New York awarded Nikola approximately $165 million plus interest. Marathon Digital Holdings, Inc. (NASDAQ: MARA) rose 17.1% to $10.25 after Bitcoin reached $35,000 for the first time since 2022. Argo Blockchain plc (NASDAQ: ARBK) shares jumped 17% to $1.2750 after jumping over 12% on Monday. Medpace Holdings, Inc. (NASDAQ: MEDP) gained 16.5% to $265.03 after the company released its third-quarter results. Hesai Group (NASDAQ: HSAI) climbed 16.4% to $11.08. Amneal Pharmaceuticals, Inc. (NYSE: AMRX) rose 15.7% to $3.8881. Amneal Pharmaceuticals sees preliminary third-quarter net revenue of $610 million to $620 million. Diversified Healthcare Trust (NASDAQ: DHC) surged 15.1% to $1.98 as the company issued ...

U.S. stocks traded higher Tuesday, with the Nasdaq Composite gaining over 100 points. Here are some big stocks recording gains in the trading session. ImmunityBio, Inc. (NASDAQ: IBRX) shares rose 31.4% to $1.88. Aspen Aerogels, Inc. (NASDAQ: ASPN) shares surged 27.8% to $8.52. Travelzoo (NASDAQ: TZOO) gained 24.8% to $6.56 following strong quarterly results. Agilysys, Inc. (NASDAQ: AGYS) jumped 21.5% to $77.62 after it reported second-quarter results. Stitch Fix, Inc. (NASDAQ: SFIX) gained 17.7% to $3.7550. Nikola Corporation (NASDAQ: NKLA) rose 17.3% to $1.1197. Nikola, on Oct. 20, said an arbitration panel in New York awarded the company approximately $165 million plus interest. Marathon Digital Holdings, Inc. (NASDAQ: MARA) shares climbed 17.1% to $10.25 after Bitcoin reached $35,000 for the first time since 2022. Medpace Holdings, Inc. (NASDAQ: MEDP) rose 16.5% to $265.03 after the company released its third-quarter results. Amneal Pharmaceuticals, Inc. (NYSE: AMRX) jumped 15.7% to $3.8881. Amneal Pharmaceuticals sees preliminary third-quarter net revenue of $610 million to $620 million. Diversified Healthcare Trust (NASDAQ: DHC) gained 15.1% to $1.98 as the company issued a monthly SHOP performance update. MicroStrategy Incorporated (NASDAQ: MSTR) rose 15% to $433.80 as Bitcoin continues to rise on spot ETF optimism. Riot ...
Above 50MA
37.18%
Net New Highs
+51081